Deutsche Bank and Ant International Announce Strategic Partnership to Provide Integrated Cross-Border Payment Solutions to Global Merchants
Deutsche Bank and Ant International have announced their strategic partnership to provide more comprehensive payment solutions for businesses of all sizes in Europe and Asia, by combining their expertise and leveraging Ant International’s proprietary tokenisation and AI-based FX technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609586580/en/
From Left to Right: Sabih Behzad, Head of Digital Assets & Currencies Transformation for Deutsche Bank, Chintan Shah, Head of Corporate Coverage for APAC & MEA at Deutsche Bank, Kriti Jain, Head of New Economy Coverage APAC and Head of New Economy Cash Solutions Sales APAC & MEA at Deutsche Bank, Leiming Chen, Chief Sustainability Officer at Ant International, Yi Zhou, Chief Financial Officer at Ant International, Kelvin Li, General Manager of Platform Tech at Ant International and Yanyi Liang, Head of Whale Treasury Platform at Ant International
The bank will collaborate with Ant International’s Embedded Finance unit on a series of global treasury management and cross-border payment innovations, including tokenised deposits, stablecoin, and its Time-Series Transformer (TST) FX Model.
Deutsche Bank will be the first German bank to facilitate Ant International’s blockchain-based real-time treasury management platform to enable real-time fund transfers between Ant International’s intragroup entities. This will enable more efficient and transparent global treasury management for Ant.
In addition, the two sides will also explore cross-border payment innovations, including tokenised bank deposits, stablecoin and Ant International’s Falcon TST FX Model, to help Ant International and its clients reduce FX-related cost and risks. Both companies will also further look into the applications of stablecoins for global payments, including real-time cross-border treasury management for Ant’s entities, reserve management and on-ramp and off-ramp services.
Deutsche Bank will also work with Antom, a merchant payment and digitisation services provider, to scale up their collaboration to extend Antom’s acquiring solutions for merchants in EMEA, enabling them to be seamlessly integrated with more payment solutions.
The bank will also support WorldFirst’s suite of payments-related solutions for SMEs in e-commerce and cross-border trade, including but not limited to account collections, payments and FX services. It will also enable the account and financial service provider to access its global network to serve its clients.
Ole Matthiessen, Head of Corporate Bank APAC & MEA and Global Head of Cash Management for Deutsche Bank, said: “We are delighted to strategically cooperate with Ant International. We will leverage our broad product capabilities and strong global network to deliver seamless and secure payment solutions to Ant International and its customers in Europe and Asia. Given the dynamic landscape of financial services, we see great potential to collaborate with Ant International, as one of the world’s leading financial technology providers, to develop innovative payment solutions and transform the future of treasury management.”
Kelvin Li, General Manager of Platform Tech at Ant International, said: “With a dynamic fintech landscape, Europe is fast-becoming a key hub for global digital payment innovation. We are pleased to deepen our commitment to the region through this collaboration with Deutsche Bank, supporting the development of more seamless, secure and inclusive cross border payment solutions. By combining our digital and payment capabilities with a global leading financial institution, we aim to deliver enhanced payment experiences that meet the evolving needs of global businesses and consumers.”
Expanding on a client relationship that has been in place since 2019, the two sides signed a Memorandum of Understanding (MoU) on June 8 in Munich, Germany to deepen the strategic collaboration.
About Deutsche Bank
Deutsche Bank provides retail and private banking, corporate and transaction banking, lending, asset and wealth management products and services as well as focused investment banking to private individuals, small and medium-sized companies, corporations, governments and institutional investors. Deutsche Bank is the leading bank in Germany with strong European roots and a global network.
About Ant International
With headquarters in Singapore and main operations across Asia, Europe, the Middle East and Latin America, Ant International is a leading global digital payment, digitisation and financial technology provider. Through collaboration across the private and public sectors, our unified techfin platform supports financial institutions and merchants of all sizes to achieve inclusive growth through a comprehensive range of cutting-edge digital payment and financial services solutions. To learn more, please visit https://www.ant-intl.com/
About Antom
Ant International's Antom is the leading payment and digitisation services provider for merchants around the world. It offers unified merchant payment solutions to serve businesses of all sizes. Antom supports merchants to integrate over 300 payment methods, enabling them to connect with consumers in more than 200 markets, with the flexibility to accept payments in more than 100 currencies. Beyond payments, it provides digital marketing solutions and merchant digitisation services to help merchant streamline operations and enhance customer engagement. To learn more, please visit https://www.antom.com/.
About WorldFirst
WorldFirst offers cross-border payments and treasury services through its global business account, empowering growth for SMEs in e-commerce, trade, and the broad platform economy. WorldFirst simplifies key financial operations, including international payments, collections, currency conversions, and treasury management, all in a one-stop account. Leveraging the technological strengths of its parent company Ant International, WorldFirst delivers industry-leading transaction security and reliability. WorldFirst has supported over one million customers, enabling payments in 100+ currencies across more than 200 countries and regions. Learn more about WorldFirst at https://www.worldfirst.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250609586580/en/
Contacts
Media Contacts
Deutsche Bank
Kate Fields
Kate.fields@db.com
Ant International
Joshua Way
joshua.way@ant-intl.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom